Affiliations 

  • 1 Northern Genetics Service, Newcastle Upon Tyne NHS Foundation Trust, International Centre for Life, Newcastle upon Tyne, UK
  • 2 Murdoch Childrens Research Institute, Parkville, Victoria, Australia
  • 3 Clinical Genetics Unit, Christian Medical College, Vellore, India
  • 4 Medical Genetics Center, Korba, Cairo, Egypt
  • 5 Paediatrics & Child Health, University College Cork, Cork, Republic of Ireland
  • 6 MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
  • 7 Clinical Genetics, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 8 Paediatric Neurology, Temple Street Children's University Hospital, Dublin, Republic of Ireland
  • 9 Department of Clinical Genetics, Glan Clwyd Hospital, Rhyl, Denbighshire, UK
  • 10 Division of Child Neurology, Chiba Children's Hospital, Chiba, Japan
  • 11 Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK
  • 12 Division of Child Health, Faculty of Education, Chiba University, Chiba, Japan
  • 13 Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon Tyne, UK
Genet Med, 2016 05;18(5):483-93.
PMID: 26204423 DOI: 10.1038/gim.2015.110

Abstract

PURPOSE: Cockayne syndrome (CS) is a rare, autosomal-recessive disorder characterized by microcephaly, impaired postnatal growth, and premature pathological aging. It has historically been considered a DNA repair disorder; fibroblasts from classic patients often exhibit impaired transcription-coupled nucleotide excision repair. Previous studies have largely been restricted to case reports and small series, and no guidelines for care have been established.

METHODS: One hundred two study participants were identified through a network of collaborating clinicians and the Amy and Friends CS support groups. Families with a diagnosis of CS could also self-recruit. Comprehensive clinical information for analysis was obtained directly from families and their clinicians.

RESULTS AND CONCLUSION: We present the most complete evaluation of Cockayne syndrome to date, including detailed information on the prevalence and onset of clinical features, achievement of neurodevelopmental milestones, and patient management. We confirm that the most valuable prognostic factor in CS is the presence of early cataracts. Using this evidence, we have created simple guidelines for the care of individuals with CS. We aim to assist clinicians in the recognition, diagnosis, and management of this condition and to enable families to understand what problems they may encounter as CS progresses.Genet Med 18 5, 483-493.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.